Lechat Bastien, Loffler Kelly A, Wallace Douglas M, Reynolds Amy, Appleton Sarah L, Scott Hannah, Vakulin Andrew, Lovato Nicole, Adams Robert, Eckert Danny J, Catcheside Peter G, Sweetman Alexander
Adelaide Institute for Sleep Health and FHMRI Sleep Health, Flinders University, Adelaide, South Australia, Australia.
Department of Neurology, Sleep Medicine Division, University of Miami Miller School of Medicine, Miami, FL, USA.
Nat Sci Sleep. 2022 Oct 13;14:1817-1828. doi: 10.2147/NSS.S379252. eCollection 2022.
Insomnia symptoms and sleep apnea frequently co-occur and are associated with worse sleep, daytime function, mental health and quality of life, compared to either insomnia or obstructive sleep apnea (OSA) alone. This study aimed to investigate the association of symptoms of co-morbid insomnia and sleep apnea (COMISA) with all-cause mortality.
Wisconsin Sleep Cohort data were analysed to assess potential associations between COMISA symptoms and all-cause mortality. Nocturnal insomnia symptoms were defined as difficulties initiating sleep, maintaining sleep, and/or early morning awakenings "often" or "almost always", and/or regular sedative-hypnotic medicine use. OSA was defined as an apnea-hypopnea index ≥5/hr sleep. Participants were classified as having neither insomnia symptoms nor OSA, insomnia symptoms alone, OSA alone, or COMISA symptoms. Associations between the four groups and all-cause mortality over 20 years of follow-up were examined via multivariable adjusted Cox regression models.
Among 1115 adult participants (mean ± SD age 55 ± 8 years, 53% males), 19.1% had COMISA symptoms. After controlling for sociodemographic and behavioral factors, COMISA symptoms were associated with an increased risk of all-cause mortality compared to no insomnia symptoms or OSA (HR [95% CI]; 1.71 [1.00-2.93]). OSA alone (0.91 [0.53, 1.57]) and insomnia symptoms alone (1.04 [0.55, 1.97]) were not associated with increased mortality risk.
Co-morbid insomnia symptoms and sleep apnea is associated with increased all-cause mortality risk. Future research should investigate mechanisms underpinning COMISA and the effectiveness of different treatment approaches to reduce mortality risk for this common condition.
失眠症状与睡眠呼吸暂停经常同时出现,与单纯失眠或阻塞性睡眠呼吸暂停(OSA)相比,会导致更差的睡眠、日间功能、心理健康和生活质量。本研究旨在调查共病失眠和睡眠呼吸暂停(COMISA)症状与全因死亡率之间的关联。
分析威斯康星睡眠队列数据,以评估COMISA症状与全因死亡率之间的潜在关联。夜间失眠症状定义为入睡困难、维持睡眠困难和/或清晨经常或几乎总是醒来,和/或经常使用镇静催眠药物。OSA定义为呼吸暂停低通气指数≥5次/小时睡眠。参与者被分类为既无失眠症状也无OSA、仅有失眠症状、仅有OSA或有COMISA症状。通过多变量调整的Cox回归模型检查四组与20年随访期间全因死亡率之间的关联。
在1115名成年参与者(平均±标准差年龄55±8岁,53%为男性)中,19.1%有COMISA症状。在控制了社会人口学和行为因素后,与无失眠症状或OSA相比,COMISA症状与全因死亡率风险增加相关(HR[95%CI];1.71[1.00 - 2.93])。单独的OSA(0.91[0.53, 1.57])和单独的失眠症状(1.04[0.55, 1.97])与死亡率风险增加无关。
共病失眠症状和睡眠呼吸暂停与全因死亡率风险增加相关。未来的研究应调查COMISA的潜在机制以及不同治疗方法降低这种常见疾病死亡率风险的有效性。